{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:02:47Z","timestamp":1789012967407,"version":"build-2803163510"},"reference-count":36,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,12,15]]},"DOI":"10.2169\/internalmedicine.1018-18","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T22:47:06Z","timestamp":1533854826000},"page":"3651-3657","source":"Crossref","is-referenced-by-count":7,"title":["Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease"],"prefix":"10.2169","volume":"57","author":[{"given":"Satoshi","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohkawara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuei","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Harada-Shirado","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Shichishima-Nakamura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro James","family":"Kazama","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Sayed RH, Wechalekar AD, Gilbertson JA, et al. Natural history and outcome of light chain deposition disease. Blood 126: 2805-2810, 2015.","DOI":"10.1182\/blood-2015-07-658872"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Pozzi C, Locatelli F. Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol 22: 319-330, 2002.","DOI":"10.1053\/snep.2002.33673"},{"key":"3","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"3. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127: 2375-2390, 2016.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ronco P, Plaisier E, Mougenot B, et al. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 1: 1342-1350, 2006.","DOI":"10.2215\/CJN.01730506"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gokden N, Barlogie B, Liapis H. Morphologic heterogeneity of renal light-chain deposition disease. Ultrastruct Pathol 32: 17-24, 2008.","DOI":"10.1080\/01913120701854002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Finsterer J, H\u00f6ftberger R, St\u00f6llberger C, et al. Sudden death possibly related to lenalidomide given for cardiac and muscle AL amyloidosis secondary to light chain deposition disease. J Oncol Pharm Pract 19: 170-174, 2013.","DOI":"10.1177\/1078155212443991"},{"key":"7","unstructured":"7. Pozzi C, Fogazzi GB, Banfi G, et al. Renal disease and patient survival in light chain deposition disease. Clin Nephrol 43: 281-287, 1995."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366: 1770-1781, 2012.","DOI":"10.1056\/NEJMoa1114083"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123-2132, 2007.","DOI":"10.1056\/NEJMoa070594"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23: 2147-2152, 2009.","DOI":"10.1038\/leu.2009.147"},{"key":"11","unstructured":"11. Said S, J Cooper C, C Nwosu A, et al. Hypertension, renal failure, and edema in a 38-year-old man: light chain deposition disease; a case report and review of the literature. J Nephropathol 3: 63-68, 2014."},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Fermand JP, Bridoux F, Kyle RA, et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 122: 3583-3590, 2013.","DOI":"10.1182\/blood-2013-05-495929"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Correia SO, Santos S, Malheiro J, et al. Monoclonal gammopathy of renal significance: diagnostic workup. World J Nephrol 6: 72-78, 2017.","DOI":"10.5527\/wjn.v6.i2.72"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hall CL, Peat DS. Light chain deposit disease: a frequent cause of diagnostic difficulty. Nephrol Dial Transplant 16: 1939-1941, 2001.","DOI":"10.1093\/ndt\/16.9.1939"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kasagi T, Nobata H, Suzuki K, et al. Light chain deposition disease diagnosed with laser micro-dissection, liquid chromatography, and tandem mass spectrometry of nodular glomerular lesions. Intern Med 56: 61-66, 2017.","DOI":"10.2169\/internalmedicine.56.7275"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Leung N, Lager DJ, Gertz MA, et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 43: 147-153, 2004.","DOI":"10.1053\/j.ajkd.2003.09.020"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Short AK, O'Donoghue DJ, Riad HN, et al. Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature. Am J Nephrol 21: 237-240, 2001.","DOI":"10.1159\/000046254"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lu L, Payvandi F, Wu L, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77: 78-86, 2009.","DOI":"10.1016\/j.mvr.2008.08.003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Furukawa M, Ohkawara H, Ogawa K, et al. Autocrine and paracrine interactions between multiple myeloma cells and bone marrow stromal cells by growth arrest-specific gene 6 cross-talk with interleukin-6. J Biol Chem 292: 4280-4292, 2017.","DOI":"10.1074\/jbc.M116.733030"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26: 2326-2335, 2012.","DOI":"10.1038\/leu.2012.119"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hsu AK, Quach H, Tal T, Prince HM, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 117: 1605-1613, 2011.","DOI":"10.1182\/blood-2010-04-278432"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol 33: 2803-2811, 2015.","DOI":"10.1200\/JCO.2014.59.5363"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Keeling J, Herrera GA. The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage. Contrib Nephrol 153: 116-134, 2007.","DOI":"10.1159\/000096764"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108: 618-621, 2006.","DOI":"10.1182\/blood-2005-10-4184"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Lorenz EC, Gertz MA, Fervenza FC, et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 23: 2052-2057, 2008.","DOI":"10.1093\/ndt\/gfm918"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Hideshima T, Chauhan D, Richardson P, et al. NF-\u03baB as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647, 2002.","DOI":"10.1074\/jbc.M200360200"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kastritis E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadjikonstantinou V, Dimopoulos MA. Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 94: 300-302, 2009.","DOI":"10.3324\/haematol.13548"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Cohen C, Royer B, Javaugue V, et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 88: 1135-1143, 2015.","DOI":"10.1038\/ki.2015.201"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Weisel KC, B\u00f6ckeler M, Bianchi L, et al. Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide. Int J Hematol 89: 91-94, 2009.","DOI":"10.1007\/s12185-008-0228-7"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Jimenez-Zepeda VH, Vajpeyi R, John R, et al. Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation. Int J Hematol 96: 125-131, 2012.","DOI":"10.1007\/s12185-012-1090-1"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Gkotzamanidou M, Terpos E, Kastritis E, et al. Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach? Clin Lymphoma Myeloma Leuk 14: e179-181, 2014.","DOI":"10.1016\/j.clml.2014.06.002"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47: 1466-1475, 2007.","DOI":"10.1177\/0091270007309563"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22: 1485-1493, 2008.","DOI":"10.1038\/leu.2008.131"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Royer B, Arnulf B, Martinez F, Roy L, et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 65: 642-648, 2004.","DOI":"10.1111\/j.1523-1755.2004.00427.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Mohty M, Harousseau JL. Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. Haematologica 99: 408-416, 2014.","DOI":"10.3324\/haematol.2013.096149"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371: 895-905, 2014.","DOI":"10.1056\/NEJMoa1402888"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/24\/57_1018-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T14:33:22Z","timestamp":1604759602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/24\/57_1018-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,15]]},"references-count":36,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1018-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,15]]}}}